Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase NA 24Phase 3 14Phase 1 6Phase 2/3 3Phase EARLY_PHASE1 2Phase 1/2 2Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Head & Neck 2Breast 2Genitourinary 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoadjuvant Therapy × Breast × Clear all
NCT07217990 2026-02-17

NoCUT-BC

Ohio State University Comprehensive Cancer Center

Phase 1/2 Not yet recruiting
84 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00290745 2020-12-04

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

University of California, San Francisco

Phase 1/2 Completed
79 enrolled 15 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡